Pharmacokinetics, tissue distribution and excretion of vinflunine

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 31, Issue 2, 2006, Pages 59-64

  Zhao, Xiao Ping ^a   Liu, Xiao Quan ^a   Wang, Yong Sheng ^a   Wang, Huan ^a   Wang, Guang Ji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Excretion; Pharmacokinetics; Tissue distribution; Vinflunine

Indexed keywords

PLASMA PROTEIN; VINFLUNINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILE FLOW; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TISSUE LEVEL; FECES; FEMALE; MALE; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; RAT; TISSUE DISTRIBUTION; TISSUE PERFUSION; TUMOR; URINARY EXCRETION;

EID: 33746715064     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191120     Document Type: Article

References (17)

1. Donehover R.C., Rowinsky E.K., Devita V.T., Hellman S., Rosenberg S.A. (1993). In Cancer: Principles and Practice of Oncology, JB Lippincott Co., Philadelphia, PA, 409-417.
2. Jordan M.A., Thrower D., Wilson L. (1991): Mechanism of inhibition by Vinca alkaloids. Cancer Res., 51, 2212-2222.
3. Wilson L., Panda D., Jordan M.A. (1999): Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators. Cell Struct. Funct., 24, 329-335.
4. Fahy J., Duflos A., Ribet J.P. (1997): Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J. Am. Chem. Soc., 119, 8576-8577.
5. Bunn P.A. Jr., Kelly K. (1998): New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res., 4, 1087-1100.
6. Crown J. (1997): Optimising treatment outcomes: a review of current management strategies in first-line chemotherapy of metastatic breast cancer. Eur. J. Cancer, 33 suppl. 7, S15-S19.
7. Johnson S.A., Harper p., Hortobagyi G.N., Pouillart P. (1996): Vinorelbine: an overview. Cancer Treat. Rev., 22, 127-142.
8. Jordan M.A., Wilson L. (1990): Kinetic analysis of tubulin exchange at microtubule ends at low vinblastine concentrations. Biochemistry, 29, 2730-2739.
9. Kruczynski A., Barret J.M., Etievant C., Colpaert F., Fahy J., Hill B.T. (1998): Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem. Pharmacol., 55, 635-648.
10. Kruczynski A., Colpaert F., Tarayre J.P., Mouillard P., Fahy J., Hill B.T. (1998): Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother. Pharmacol., 41, 437-447.
11. Hill B.T., Fiebig H.H., Waud W.R., Poupon M.F., Colpaert F., Kruczynski A. (1999): Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur. J. Cancer, 35, 512-520.
12. Kruczynski A., Hill B.T. (2001): Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit. Rev. Oncol. Hematol., 40, 159-173.
13. Singer W.D., Himes R.H. (1992): Cellular uptake and tubulin binding properties of four Vinca alkaloids. Biochem. Pharmacol., 43, 545-551.
14. Holwell S.E., Hill B.T., Bibby M.C. (2001): Anti-vascular effects of vinflunine in the MAC ISA transplantable adenocarcinoma model. Br. J. Cancer, 84, 290-295.
15. Bennouna J., Fumoleau P., Armand J.P., Raymond E., Campone M., Delgado F.M., Puozzo C., Marty M. (2003): Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann. of Oncol., 14, 630-637.
16. Etiévant C., Barret J.M., Kruczynski A. Perrin D. Hill B.T. (1998): Vinflunine (20′,20′-difluoro-3′,4′- dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Inveat. New Drugs, 16, 3-17.
17. Jacquesy J.C., Jouannetaud M.P. (2005): Vinflunine: anew anti-cancer fluorinated agent derived from Vinca-alkaloids. Ann. Pharm. Fr., 63, 28-34.